本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Innate Pharma SA

1.89
-0.0200-1.05%
成交量:4.54萬
成交額:8.58萬
市值:2.12億
市盈率:-2.94
高:1.92
開:1.92
低:1.87
收:1.91
52周最高:2.71
52周最低:1.17
股本:1.12億
流通股本:8,844.50萬
量比:4.09
換手率:0.05%
股息:- -
股息率:- -
每股收益(TTM):-0.6440
每股收益(LYR):-0.6458
淨資產收益率:-271.37%
總資產收益率:-46.60%
市淨率:-4.56
市盈率(LYR):-2.93

資料載入中...

2020/04/14

非美公司披露報告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/14

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/10

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/10

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/03

超過5%披露

Statement of acquisition of beneficial ownership by individuals
2020/01/14

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/09

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/02

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/13

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/09

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/06

非美公司披露報告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/10/25

超過5%披露

General statement of acquisition of beneficial ownership
2019/10/23

超過5%披露

Statement of acquisition of beneficial ownership by individuals
2019/10/17

[補充]招股説明書

Filing under Securities Act Rules 163/433 of free writing prospectuses
2019/10/17

[補充]招股説明書

Filing under Securities Act Rules 163/433 of free writing prospectuses
2019/10/11

SEC問詢函

[Cover]Correspondence
2019/10/11

SEC問詢函

[Cover]Correspondence
2019/10/04

[修訂]招股説明書

[Amend] Registration statement for certain foreign private issuers
2019/09/20

招股説明書

Registration statement for certain foreign private issuers